Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.10, read 2026-11-02
Ethical does not pass the values gate
Price31.27 USD
Fair value37.00
Ethical score70.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-27Read Accumulation29.01+7.8% to today ✓Markdown gives way to Accumulation first Accumulation read since July
2026-10-02Read Markdown29.95+4.4% to today Markup gives way to Markdown after a 17% slide in 6 weeks
2026-08-23Read Markup35.87-12.8% to today Accumulation gives way to Markup
2026-07-02Read Accumulation36.49-14.3% to today First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Brookfield Renewable Corp holds its Accumulation at $31.27. Consolidating, no directional conviction, held for 56 days.
As held on the ledger · 2026-11-05
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 56 days
Price at the screen
$31.27
Valuation
N/A trailing · -65.83 forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
33.64%
Below 33%
Interest-bearing debt is 33.6% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
2.53%
Below 49%
Money owed to the company is 2.5% of assets, under the 49% limit.
Pass
Revenue purity
3.67%
Below 5%
Only 3.7% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Brookfield Renewable's business is in a permissible area, but its interest-bearing debt is about 34% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BEPC's ethical verdict changes
Today BEPC does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 15% discount to our $37.00 fair value, weak competitive moat, 28.00% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 15.5% discount to the base estimate.
Where our models see it going: fair-value estimate $37.00, with a range of $32.00 to $43.00, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Renewables portfolio drowning in deepening losses
Picture a hydro dam or wind farm humming away, yet the parent company's accounts bleed red at every turn. Brookfield Renewable shows revenue sliding 3 percent, a profit margin of minus 122 percent and return on equity at minus 48 percent. The weak moat and negative forward earnings multiple of 62.7 times confirm the business is not translating its green assets into sustainable cash. We therefore pass, despite the apparent margin of safety to the 42 dollar consensus target.
The ethical screen clears, yet that only removes one objection. Core operations remain under pressure and the hold rating from analysts reflects the lack of visibility on a turnaround. A weak competitive position in a capital-intensive sector leaves little room for error when growth has already turned negative.
High leverage and exposure to power price swings add further fragility. Any recovery in margins would need sustained favourable conditions that have so far failed to materialise. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BEPC trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Accumulation$30.75+5.5%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it none, with a mean price target of $41. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Accumulation$29.15+0.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it none, with a mean price target of $41. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$29.15+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it none, with a mean price target of $41. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Accumulation$29.15-1.5%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it none, with a mean price target of $41. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Accumulation$29.59+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it none, with a mean price target of $41. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Accumulation$29.59+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it none, with a mean price target of $41. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$29.59+2.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it none, with a mean price target of $41. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$29.01+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it none, with a mean price target of $41. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it none, with a mean price target of $41.
2026-10-20Markdown$28.93-2.4%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (6 analysts) rates it none, with a mean price target of $41.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
